Professor A. M. El-Mowafy led a team of researchers from Mansoura University, Egypt, who studied DHA’s effects on solid tumours growing in mice, as well as investigating how this fatty acid interacts with cisplatin, a chemotherapy drug that is known to cause kidney damage.
El-Mowafy said, “DHA elicited prominent chemopreventive effects on its own, and appreciably augmented those of cisplatin as well. Furthermore, this study is the first to reveal that DHA can obliterate lethal cisplatin-induced nephrotoxicity and renal tissue injury.”
DHA is an omega-3 fatty acid that is commonly found in cold-water fish oil, and some vegetable oils. It is a major component of brain gray matter and of the retina in most mammalian species and is considered essential for normal neurological and cellular developments.
According to the authors, “While DHA has been tentatively linked with protection against cardiovascular, neurological and neoplastic diseases, there exists a paucity of research information, in particular regarding its interactions with existing chemotherapy drugs”. The researchers found that, at the molecular level, DHA acts by reducing leukocytosis (white blood cell accumulation), systemic inflammation, and oxidative stress – all processes that have been linked with tumour growth.
El-Mowafy and his colleagues have called for greater deployment of omega-3 in the fight against cancer. They write, “Our results suggest a new, fruitful drug regimen in the management of solid tumors based on combining cisplatin, and possibly other chemotherapeutics, with DHA.”
Article: M E Elmesery, M M Algayyar, H A Salem, M M Darweish and A M El-Mowafy, 'Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides', Cell Division (in press)
- Omega Fatty Acids DHA And AA Take Center Stage At Asian Conference On Pediatric Nutrition
- Inaccurate Reporting On Recent Omega-3 Alzheimer's Study?
- Omega-3 Fatty Acids Protect Against Blindness, Study Says
- American Heart Association Issues First-Ever Statement For Management Of Trigylcerides That Includes Intake Recommendations For Omega-3 EPA And DHA
- Omega-3 Fatty Acids May Lower Prostate Cancer Genetic Risk